We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.

Start Date28 Apr 2025

Sponsor / Collaborator

Metro International Biotech LLC

CTRI/2024/11/077325

/ Not yet recruitingPhase 4

To study the effectiveness of Plum 2% Niacinamide & Rice Water Face Wash for skin brightening, hydration and softness - NIL

Start Date03 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Nicotinamide

100 Translational Medicine associated with Nicotinamide

100 Patents (Medical) associated with Nicotinamide

19,766

Literatures (Medical) associated with Nicotinamide

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Do human adipose stem cell-derived artificial insulin-producing cells develop tumorigenic characteristics throughout differentiation?

Article

Author: Dayer, Dian ; Jafarinia, Mojtaba ; Salehi Babadi, Parastoo ; Forouzanfar, Mohsen

BACKGROUND:

Artificial insulin-producing cells (IPCs) used to treat diabetes mellitus type 1 (DMT1) are naturally hampered by their carcinogenicity. This in vitro study aimed to examine the carcinogenic potential of IPCs produced by the differentiation of human adipose tissue-derived mesenchymal stem cells (hADSCs).

METHODS AND RESULTS:

hADSCs were transformed into IPCs by administering insulin-transferrin, selenium (ITS), and nicotinamide in a 14-day differentiation protocol. The cells were transfected with 20 μg of pure Pdx1-pIRES recombinant vector on the tenth day of differentiation. The successful transfection was confirmed by Pdx1 overexpression and GFP fluorescence activity. The differentiated cells' capacity to release insulin and glucose-dependent C-peptide was used to evaluate their functionality. Gene expression was assessed using real-time PCR. Meanwhile, protein expression was investigated using western blotting. The transfected cells exhibited fluorescence activity and Pdx1 overexpression. The differentiated IPCs were able to secrete C-peptide and insulin. The artificial IPCs showed significantly reduced Oct4 and Nanog expression. However, the differentiation process induced a noticeable elevation in tPA expression. The artificial IPCs expressed much lower c-MYC expression compared to undifferentiated hADSCs. The differentiated cells exhibited a significant elevation in Glut2, MMP-2, CD24, P16, and P21 expression.

CONCLUSIONS:

The differentiation technique used in this work produced functional beta-like cells devoid of typical markers of stem cells. The synthetic IPCs displayed characteristics of newly generated β-like cells. The artificial IPCs showed no signs of expressing tumor-associated markers. The findings imply that the artificial IPC cells lack tumor characteristics in vitro.

01 Sep 2025·NEUROPHARMACOLOGY

Sirtuins modulators mitigate hypoxia-induced cell death due to changes in histone 3 acetylation, and mitochondrial function, dynamics, and content

Article

Author: Rosenstock, Tatiana Rosado ; Souza E Silva, Luiz Felipe ; Siena, Amanda ; Yuzawa, Jessica Mayumi

Hypoxia is a key environmental factor linked to neurodevelopmental complications, primarily through its impact on mitochondrial dysfunction. Given that sirtuins regulate mitochondrial and cellular metabolism, we aimed to investigate whether pharmacological modulation of sirtuins could protect neurons from hypoxia-induced mitochondrial dysfunction and cell death. To explore this, primary cortical neurons from male Wistar rats (control) and Spontaneously Hypertensive Rats (a model for neonatal hypoxia and schizophrenia) were exposed to cobalt chloride (CoCl₂) to chemically induce hypoxia. Neurons were also treated with Nicotinamide (50 μM), Resveratrol (0.5 μM), and Sirtinol (5 μM) to modulate sirtuin activity. We first assessed histone deacetylation, cell death, mitochondrial calcium retention capacity, mitochondrial membrane potential, and levels of reactive oxygen species (ROS). In addition, we analysed the expression of genes related to mitochondrial metabolism, dynamics, and biogenesis, as well as high-energy compound levels. Our data indicate that both chemical and neonatal hypoxia caused mitochondrial depolarization, reduced calcium retention, increased ROS levels, and elevated Nfe2l2 expression in primary cortical neurons. Hypoxia also led to increased expression of genes associated with mitochondrial biogenesis and fission, as well as reduced ATP levels and elevated pyruvate and lactate levels. Importantly, treatment with sirtuin modulators enhanced neuron viability, likely by further increasing Nfe2l2 expression and reducing ROS production. These modulators also improved metabolic outcomes, including higher ATP levels, and normalised pyruvate and lactate production, as well as mitochondrial fusion gene expression. Collectively, our findings suggest that sirtuin modulators could mitigate hypoxia-induced damage and may represent a potential therapeutic strategy for managing neurodevelopmental disorders.

01 Sep 2025·Comparative Biochemistry and Physiology D-Genomics & Proteomics

Dynamic metabolic profiling of sea cucumbers (Apostichopus japonicus) under predation stress

Article

Author: Wang, Shuo ; Sun, Yongxin ; Song, Jian ; Qu, Liang ; Wang, Qingzhi ; Wang, Meng ; Wang, Chong ; Zhao, Chong

The present study utilized non-targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) to investigate the metabolomic responses of sea cucumber (Apostichopus japonicus) juveniles under predation stress induced by sea stars (Asterina pectinifera) at various time points (3 h, 12 h, 72 h, and 96 h). The findings revealed significant temporal changes in the metabolic profiles of the sea cucumber juveniles under predation stress, with 25, 72, 55, and 53 metabolic products exhibiting significantly different expression levels at each time point (positive ion mode, P < 0.05), respectively. Notably, the impact of predation stress was most pronounced at the 12-h mark. Multivariate statistical methods, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA), further confirmed distinct clustering of the experimental group away from the control group at each time point, with the most pronounced separation occurring at 12 h, indicating a significant and time-dependent metabolic response to predation stress. Key metabolic pathways associated with predation stress were identified, such as carbon metabolism, pentose phosphate pathway, purine metabolism, riboflavin metabolism, longevity regulation, and antifolate resistance pathways, by integrating variable importance in the projection (VIP), fold change (FC), and P-value. KEGG enrichment analysis highlighted significant expression changes of key metabolites like carbamoyl phosphate, gluconolactone, inosine, 2'-deoxyguanosine, and adenylate in response to predation stress, potentially related to energy metabolism, antioxidant defense, signal transduction, and cellular stress responses. The study provides novel insights into the metabolic adaptability of sea cucumber juveniles to predation stress.

News (Medical) associated with Nicotinamide

21 May 2025

·www.einpresswire.com

AOB Pharma reveals new metabolomic insights of B244, suggesting investigation of potential new avenues for treatment

AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment CAMBRIDGE, MA, UNITED STATES, May 21, 2025 / EINPresswire.com / -- AOB Pharma reveals new mechanistic insights via metabolomic analysis of B244, supporting clinical readouts and suggesting investigation of potential new avenues for treatment • B244 produces numerous skin-beneficial metabolites including ceramides, retinoids, tocopherol, and niacinamide • The presence of these anti-inflammatory and skin-beneficial compounds suggest additional ways that B244 can improve atopic dermatitis and other inflammatory skin diseases • Mining of additional metabolomic data may additionally suggest new indications for which B244 can be used • Select data will be presented by Dan Brownell, AOBiome’s Senior Director of R&D, at the Dermatology Drug Development Summit Europe, taking place in Berlin May 27-28, 2025 CAMBRIDGE, MA, May 21, 2025. AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions, shares new data showing that B244, their lead asset, secretes a suite of anti-inflammatory and beneficial skin metabolites. Metabolomic analysis of B244 has revealed the production of various ceramides, retinoids, tocopherol, niacinamide, and many other compounds critical for skin health. These compounds, in addition to the previously understood mechanisms of action, further highlight the multifactorial benefits of B244 for the potential treatment of additional inflammatory diseases. Ceramides are essential lipids that help maintain the skin's natural barrier, which is often compromised in people with atopic dermatitis. By replenishing ceramide levels, the skin can maintain moisture, reduce dryness, and protect the skin from irritants and allergens. This strengthens the skin’s defense, soothes inflammation, and reduces flare-ups, making ceramides a tool in the maintenance of skin health. Other metabolites produced by B244 have similar potential benefits that justify investigation for use in treatment, including reducing inflammation, antioxidant effects, improvement in skin appearance associated with various skin disorders. “B244 is clearly more than simply a probiotic: these active metabolites have the potential to support the skin in multiple ways simultaneously, unlike any product currently in the marketplace. There is tremendous potential here to revolutionize our understanding of the role of bacteria in skin health and resilience” says Peter Lio, MD, Founding Partner, Medical Dermatology Associates of Chicago. AOBiome is currently preparing to initiate a global Phase 3 study to evaluate B244 for the treatment of mild-to-moderate Atopic Dermatitis and associated moderate-to-severe itch, following the successful completion of a 547 patient Phase 2b study. In addition to the previously understood mechanisms of B244, these new metabolomic insights further suggest the range of improvements of AD symptoms seen clinically. “From an evolutionary standpoint, this further highlights the potential need for ammonia oxidizing bacteria for not only maintaining healthy skin, but treating inflammatory conditions that we did not evolve to have” says President and CEO Todd Krueger. About B244 AOBiome’s B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be safe and well-tolerated in clinical studies to date. Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: https://www-nature-com.libproxy1.nus.edu.sg/articles/s41598-021-93299-1 . About AOB Pharma, Inc. AOB Pharma, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at AOBiome.com . For Media Inquiries: Jim Hoffman AOBiome Therapeutics +1 617-639-9980 Press@aobiome.com Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Microbial therapy

26 Mar 2025

·heidelberg-pharma.com

PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025

Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting its latest ADC research results and advancement for its Exatecan-based ADC technology platform at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois, USA, from 25 to 30 April. In addition to its proprietary Amanitin-based ADC technology, Heidelberg Pharma has developed a diverse ADC toolbox designed to overcome tumor resistance through multiple mechanisms, enabling targeted treatment across various cancer types. Dr. Sarah-Jane Neuberth will present preclinical findings on HDP-201, Heidelberg Pharma´s novel Exatecan-based, multimeric linker ADC, called ETAC technology, which is being developed for the treatment of colorectal cancer. The findings indicate target-specific potency, strong anti-tumor efficacy, and high tolerability. Dr. Pablo Ruedas Batuecas will demonstrate the potential of computational modeling for optimizing NAMPT inhibitors (NAMPTi) designed in silico as payloads and as a mode of action (MOA) in ADC technology. This novel technology approach has the potential to overcome the current limitations of cancer therapies by targeting both dividing and non-dividing cancer cells. AACR Annual Meeting 2025 Details of the conference and presentations are as follow: Poster: HDP-201 – a novel multimeric linker exatecan-based ADC targeting Guanylyl cyclase C (GCC) for treatment of gastrointestinal malignancies Abstract number: 1558 Session: Antibody-Based Cancer Therapeutics 1 Presentation time: 28 April, 9:00 am – 12:00 pm CST Speaker: Dr. Sarah-Jane Neuberth, Associate Director In Vivo Biology Link to abstract: https://www.abstractsonline.com/pp8/#!/20273/presentation/2830 The ETAC HDP-201 is directed against the surface protein GCC (guanylyl cyclase C), which is highly overexpressed in gastrointestinal malignancies, including gastric and colorectal cancers. HDP-201 showed potent anti-tumor efficacy in preclinical models, including complete tumor remission of GCC-expressing CDX models and significant inhibition of tumor growth in gastrointestinal PDX models. A single intravenous dose of 60 mg/kg of HDP-201 was well tolerated in cynomolgus monkeys, with no severe toxicity. These findings underscore the potential of HDP-201 as a promising new therapeutic option for GCC-positive gastrointestinal malignancies. Talk (Minisymposium): In silico optimized NAMPT inhibitor for targeted delivery by ADC as novel therapeutic modality for treatment of liquid and solid malignancies Abstract number: 1162 Stream: Antibody-Based Cancer Therapeutic Agents Presentation time: 27 April, 3:00 – 5:00 pm CST Speaker: Dr. Pablo Ruedas Batuecas, Scientist Chemistry Link to abstract: https://www.abstractsonline.com/pp8/#!/20273/presentation/2815 Nearly half of the US Food and Drug Administration (FDA) approved ADCs are based on microtubule inhibitors, that selectively target dividing cancer cells but fail to eradicate non-dividing tumor stem cells, potentially leading to resistance and tumor relapse. Inhibition of NAMPT, the rate-limiting enzyme in the salvage biosynthetic pathway of NAD+ starting from nicotinamide, induces cell death due to energy shortage in both dividing and non-dividing cell populations. This is a promising approach to overcome current therapy limitations by utilizing novel payloads. ADCs based on in silico designed NAMPTi as payloads show promising in vitro and in vivo results, highlighting the potential of NAMPT inhibition as an emerging MOA in ADC technology that enhances the targeted drug delivery to different cell lines.

AACRADC

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Nicotinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00036	Nicotinamide	A11HA01	DB02701

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Coronary Artery Disease	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Myocarditis	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Vitamin B Deficiency	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Pellagra	Japan	Catalent Japan KK	27 Oct 1961
Acne Vulgaris	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Hyperphosphatemia	Phase 2	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03061474 (NEAT, Pubmed \| Alzheimers Res Ther)	Phase 2	Alzheimer Disease pTau231	47	Nicotinamide 1500 mg PO BID	jqiqpiwics(riyfwaspju) = iqlerrxpyx fpitpceufz (xfxxlyelwc ) View more	Negative	11 Mar 2025
				Placebo	mfmxfdpqxg(nkigloyujv) = wqcmbyqqpm tjlwsczici (ynwfsneetj )
NCT02416739 (Pubmed) Manual	Phase 2	EGFR Mutation Lung Cancer EGFR Mutation	110	Nicotinamide	ndvefwutqa(kjgyylcqzy) = vmbdvxkvwz hvanojxdpq (qngomkgfly, 10.4 - 18.3) View more	Positive	09 Apr 2024
				Placebo	ndvefwutqa(kjgyylcqzy) = tbjcugvsse hvanojxdpq (qngomkgfly, 9.0 - 13.2) View more
NCT02416739 (AACR2024) Manual	Phase 2	EGFR Mutation Lung Cancer EGFR Mutation	110	Nicotinamide	jrpwhyssvz(gqxipkbmot) = odtkizqhte kqhwaxwqmy (vwckwnelal, 10.4 - 18.3) View more	Positive	05 Apr 2024
				Placebo	jrpwhyssvz(gqxipkbmot) = ywlkwisfhq kqhwaxwqmy (vwckwnelal, 9.0 - 13.2) View more
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	tyvczktiyw(kefgwpydpt) = vniakzmuno ttfnhkbbjp (evhsjtdqzq, vwhxarxqiz - rzfqomglqu) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	tyvczktiyw(kefgwpydpt) = tpizalsbqs ttfnhkbbjp (evhsjtdqzq, aaylaurcpo - dnnyjipsge) View more
NCT03061474 (NEAT, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	46	Nicotinamide (Nicotinamide)	ziywxlowky(ueblkavlhe) = wfaqxljnff eohznonvjw (llvwsdtgpt, 14.46) View more	-	17 Oct 2023
				Placebo Comparator (Placebo)	ziywxlowky(ueblkavlhe) = hvgcwovnul eohznonvjw (llvwsdtgpt, 10.55) View more
WCD2023	Not Applicable	-	-	High broad spectrum sunscreen containing Nicotinamide and Panthenol	ybidcuxbyz(obxifboyhj) = pnqyvjqihh fqcrxmkpqu (qucelccfyi ) View more	Positive	03 Jul 2023
NCT03419364 (CTgov)	Phase 2	Pre-Eclampsia	23	nicotinamide (Nicotinamide - Pre-eclampsia)	fkoheqshld(avxykjvprr) = aynrejjexw xiuzjuluyz (ykexghggob, 9) View more	-	08 Sep 2022
				nicotinamide (Nicotinamide - Healthy Pregnant)	fkoheqshld(avxykjvprr) = arulpbpfuk xiuzjuluyz (ykexghggob, 9) View more
EADV2022	Not Applicable	Actinic Keratosis p21 positive \| DIMTIM \| p53 ... View more	12	High broad spectrum UVB-UVA sunscreen containing Nicotinamide and Panthenol	acuiftuekt(yodaxbdqqw) = oslhhfrosv waggiwgnlp (lukwvoxenw ) View more	Positive	07 Sep 2022
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	uwanfamqfu(idwrxitohd) = iyjjwruulx tjqtbionjj (nyvfichded, nqywednypx - pfroozzgwq) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	uwanfamqfu(idwrxitohd) = rhlkvriyls tjqtbionjj (nyvfichded, vkeogiuoub - fiparykawp) View more
R21 (DK104086) (ASN2020)	Not Applicable	Polycystic Kidney, Autosomal Dominant acetylated p53 \| total p53 protein \| serum creatinine ... View more	-	Niacinamide 30 mg/kg	dqxckzxxux(wjyqjklqkl) = zhkyvhopjr wlmdfiqwuo (euobhfqfti ) View more	Negative	19 Oct 2020
				Placebo	gckfcbkxjt(ffbenlfoir) = rncaiuxdoj gowxyovcim (pjfptesxic )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nicotinamide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation